Clinical Trials Logo
  1. Home
  2. Gastric Cancer Stage IV
  3. NCT04267549

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Gastric Cancer Stage IV Clinical Trial

Official title:
Efficacy and Safety of Conversion Therapy With Sintilimab in Combination With Chemotherapy and Apatinib in Patients With Stage IV Gastric Cancer

Clinical Trial Summary

This is a single-arm, phase II study aiming to evaluate the feasibility and efficacy of sintilimab (PD-1 inhibitor) in combination of apatinib and two-drug chemotherapy (S-1 plus nab-paclitaxel) as conversion therapy in patients with stage IV gastric cancer in China.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04267549
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 1, 2019
Completion date August 30, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04592211 - Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS Phase 1/Phase 2
Recruiting NCT05301465 - Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.
Active, not recruiting NCT06034964 - Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Recruiting NCT05204173 - Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis Phase 2
Recruiting NCT06342427 - Stomach Cancer Exosome-based Detection
Recruiting NCT04563975 - Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer Phase 2
Terminated NCT04168931 - Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC Phase 2
Recruiting NCT03701373 - Maintenance Treatment With S-1 in Gastric Cancer Patients Phase 2
Recruiting NCT05319639 - Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab Phase 1/Phase 2
Completed NCT03618758 - Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 Phase 1/Phase 2
Completed NCT03755440 - PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. Phase 2
Completed NCT03159585 - To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors Phase 1